13.	Related Party Transactions

Roche Holdings, Inc. and its affiliates

Related-party molecular information services revenue from Roche for the years ended December 31, 2017, 2016, and 2015 was $25,458,000, $21,493,000, and $13,132,000, respectively, which was earned under the Molecular Information Platform Program and Ex-U.S. Commercialization Agreement.

Related-party pharma research and development services revenue from Roche for the years ended December 31, 2017, 2016, and 2015 was $24,828,000, $21,984,000, and $312,000, respectively, from the reimbursement of R&D costs under the CDx Development, Immunotherapy Testing Platform Development and other programs.

Costs of related-party molecular information services from Roche were $9,014,000, $3,770,000, and $2,736,000 for the years ended December 31, 2017, 2016, and 2015, respectively, which consisted of costs incurred under the Molecular Information Platform Program and costs related to the delivery of services outside of the United States under the Ex-U.S. Commercialization Agreement.

At December 31, 2017, $10,159,000 and $3,742,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement. At December 31, 2016, $2,007,000 and $3,747,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement.

There were no other material Roche-related transactions as of December 31, 2017 and 2016 and for each of the years ended December 31, 2017, 2016, and 2015.

Other related party transactions

The Company recognized revenue of $481,000, $1,631,000, and $1,716,000 in the years ended December 31, 2017, 2016, and 2015, respectively from an arrangement with an entity affiliated with a former member of the Company’s Board executed in the year ended December 31, 2013. Of these amounts, there were no receivables included in accounts receivable as of December 31, 2017 and 2016, respectively.